Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females~2. Confirmed diagnosis of T2DM~3. 18-70 years of age~4. HbA1c ≥7.0%~Exclusion Criteria:~1. Hypersensitivity to tesofensine/metoprolol~2. Heart failure class II or greater according to the New York Heart Association (NYHA) or decompensated heart failure~3. History of myocardial infarction or stroke within 12 months prior to enrolment~4. History of coronary revascularisation or angioplasty in the last 12 months prior to enrolment~5. Patients reporting angina in the last 6 months prior to enrolment~6. Treatment with insulin and/or other injectable anti-diabetic medications, or TZDs~7. Any clinically significant cardiac arrhythmia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tesofensine/Metoprolol (Type: EXPERIMENTAL): Oral tablets Tesofensine/Metoprolol
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching oral Tesofensine/Metoprolol

Based on this trial design, predict the completion outcome and termination type (if applicable).